Jason M Held
Overview
Explore the profile of Jason M Held including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1990
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mo C, Liu J, Chen S, Storrs E, Targino da Costa A, Houston A, et al.
Nature
. 2024 Oct;
634(8036):1178-1186.
PMID: 39478210
To study the spatial interactions among cancer and non-cancer cells, we here examined a cohort of 131 tumour sections from 78 cases across 6 cancer types by Visium spatial transcriptomics...
2.
Iglesia M, Jayasinghe R, Chen S, Terekhanova N, Herndon J, Storrs E, et al.
Nat Cancer
. 2024 Oct;
5(11):1713-1736.
PMID: 39478117
Breast cancer (BC) is defined by distinct molecular subtypes with different cells of origin. The transcriptional networks that characterize the subtype-specific tumor-normal lineages are not established. In this work, we...
3.
Bansod S, Dodhiawala P, Geng Y, Bulle A, Liu P, Li L, et al.
Cell Rep
. 2024 Aug;
43(9):114667.
PMID: 39178114
Loss-of-function mutations in the C terminus of TPL2 kinase promote oncogenesis by impeding its proteasomal degradation, leading to sustained protein expression. However, the degradation mechanism for TPL2 has remained elusive....
4.
Guo Z, Luo J, Mashl R, Hoog J, Maiti P, Fettig N, et al.
Cancer Res Commun
. 2024 May;
4(6):1430-1440.
PMID: 38717161
Significance: In this research, we demonstrated that the pan-PI3K inhibitor copanlisib enhanced the cytotoxicity of eribulin in a panel of TNBC PDX models. The improved tumor growth inhibition was irrespective...
5.
Bulle A, Liu P, Seehra K, Bansod S, Chen Y, Zahra K, et al.
Nat Commun
. 2024 Mar;
15(1):2503.
PMID: 38509064
Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK inhibitor-based therapeutic combination with strong preclinical efficacy. Utilizing a...
6.
Iglesia M, Jayasinghe R, Chen S, Terekhanova N, Herndon J, Storrs E, et al.
bioRxiv
. 2023 Nov;
PMID: 37961519
Breast cancer is a heterogeneous disease, and treatment is guided by biomarker profiles representing distinct molecular subtypes. Breast cancer arises from the breast ductal epithelium, and experimental data suggests breast...
7.
Terekhanova N, Karpova A, Liang W, Strzalkowski A, Chen S, Li Y, et al.
Nature
. 2023 Nov;
623(7986):432-441.
PMID: 37914932
Chromatin accessibility is essential in regulating gene expression and cellular identity, and alterations in accessibility have been implicated in driving cancer initiation, progression and metastasis. Although the genetic contributions to...
8.
Pohl F, Germann A, Mao J, Hou S, Bakare B, Kong Thoo Lin P, et al.
Sci Adv
. 2023 Nov;
9(44):eadh2584.
PMID: 37910615
The γ-aminobutyric acid-mediated (GABAergic) system participates in many aspects of organismal physiology and disease, including proteostasis, neuronal dysfunction, and life-span extension. Many of these phenotypes are also regulated by reactive...
9.
Barlin M, Erdmann-Gilmore P, Mudd J, Zhang Q, Seymour R, Guo Z, et al.
Mol Cell Proteomics
. 2022 Dec;
22(1):100476.
PMID: 36470535
Cancer-derived extracellular vesicles (EVs) promote tumorigenesis, premetastatic niche formation, and metastasis via their protein cargo. However, the proteins packaged by patient tumors into EVs cannot be determined in vivo because...
10.
van Der Post S, Seymour R, Mooradian A, Held J
Methods Mol Biol
. 2022 May;
2399:61-84.
PMID: 35604553
Redox proteomics plays an increasingly important role characterizing the cellular redox state and redox signaling networks. As these datasets grow larger and identify more redox regulated sites in proteins, they...